In a troubling revelation, internal records disclose that top officials from the Trump administration’s Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, to discuss potential Supreme Court litigation concerning the company’s glyphosate-based herbicides. This meeting, which took place on 17 June 2025, occurred as Bayer faced a barrage of lawsuits from individuals alleging that exposure to its products, including Roundup, led to cancer diagnoses. The implications of this engagement have ignited fierce debate over corporate influence within regulatory frameworks.
High-Stakes Meeting Between Bayer and EPA Officials
The meeting, attended by Anderson and other Bayer executives, was framed as a routine regulatory discussion. However, it quickly became evident that critical litigation issues were on the agenda. According to planning emails obtained through a Freedom of Information Act request, discussions were expected to cover “supreme court action” and the ongoing legal battles facing Bayer. Notably, this gathering took place shortly before the Supreme Court requested the Trump administration’s views on whether to hear Bayer’s case.
EPA Administrator Lee Zeldin, along with key officials including Nancy Beck and Sean Donahue, participated in the discussions. The meeting’s proximity to significant legal developments has raised eyebrows, with critics questioning the extent to which corporate interests are shaping environmental policy.
The Legal Landscape and Bayer’s Defence Strategy
Bayer has been embroiled in thousands of lawsuits, with plaintiffs claiming that the company failed to adequately warn consumers about the cancer risks associated with glyphosate. The company’s strategy hinges on persuading the Supreme Court to agree with its argument that, since the EPA does not mandate a cancer warning for glyphosate products, Bayer should not be held liable for such claims. While some appellate courts have sided with Bayer, others have dismissed this line of defence, raising questions about the future of glyphosate regulation.
Since the June meeting, the Trump administration has taken several actions that appear to bolster Bayer’s legal position. In December, the solicitor general appointed by Trump argued in favour of Bayer before the Supreme Court, which subsequently agreed to hear the case. Additionally, the White House invoked the Defense Production Act to safeguard glyphosate production, further indicating a governmental alignment with Bayer’s interests.
Critics Raise Alarm Over Regulatory Capture
The involvement of Bayer in discussions with the EPA has prompted strong reactions from environmental advocates and legal experts. Nathan Donley, director of environmental health science at the Center for Biological Diversity, expressed grave concerns regarding the apparent prioritisation of corporate profits over public health. “When corporate leaders have this level of access to regulatory bodies, it underscores the disproportionate influence these entities wield over decisions affecting the health of Americans,” he stated.
Moreover, concerns have been raised about whether the EPA has granted equal opportunities for input from those adversely affected by glyphosate products. Legal advocate Whitney Di Bona highlighted the ethical implications of allowing a major pesticide company to discuss liability limitations behind closed doors, questioning if the agency has offered similar platforms for the voices of cancer victims.
Bayer’s Response and Broader Implications
In response to the scrutiny surrounding the meeting, Bayer has maintained that such interactions are standard within the regulatory framework and insisted on their transparency regarding glyphosate litigation. The company emphasised that their engagements are not exclusive to corporate stakeholders, noting that they also involve various interest groups, including environmental advocates.
However, the pattern of corporate influence over regulatory processes is alarming to many observers. Naomi Oreskes, a Harvard professor who studies corporate power in regulation, remarked that the meeting reflects a broader trend where industry leaders have privileged access to decision-makers, while public concerns may be overlooked.
Why it Matters
The revelations surrounding Bayer’s discussions with the EPA not only spotlight the intricate relationship between big corporations and regulatory agencies but also raise critical questions about public safety and transparency. As Bayer continues to navigate extensive litigation, the implications of such high-level meetings could set precedents for corporate accountability and environmental protection. With public health at stake, the need for rigorous oversight and equitable representation in regulatory processes has never been more urgent.
